Navigation Links
Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure
Date:3/29/2009

Data Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session; Results Published On-Line in The Lancet

SAN MATEO¿ Calif.¿ March 29 /PRNewswire/ -- Corthera Inc. today announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, placebo-controlled international study, demonstrated promising efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure (AHF). The report containing the detailed study results is being published on-line in the medical journal, The Lancet.

The data from 234 patients in eight countries showed that when administered with standard-of-care therapy for acute heart failure, relaxin caused rapid, substantial and sustained relief from dyspnea (breathlessness). Relaxin also demonstrated consistent trends in improvement of the hospital course of patients, prevention of heart failure worsening during hospitalization, shortening of in hospital stay and improved longer-term outcomes following discharge when compared to placebo. John R. Teerlink, M.D., professor of medicine, University of California San Francisco, Director of Heart Failure, Veterans Affairs Medical Center, San Francisco and co-principal investigator of the study, presented the findings today at a late-breaking clinical trials session at the American College of Cardiology's (ACC) 58th Annual Scientific Session in Orlando, Fla.

"The results of the study clearly indicated favorable treatment effects on symptoms, signs and outcomes in patients hospitalized with AHF," said Teerlink. "The use of relaxin led to considerable improvement in dyspnea when compared to placebo and lasted up to 14 days, longer than any therapy studied. In this study, relaxin administration was safe and well tolerated. These results provide a clear direction for the Phase III study."

Marco Metra,
'/>"/>

SOURCE Corthera Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
2. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
3. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
4. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
5. First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008
6. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
7. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
8. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
9. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
10. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
11. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... 6, 2012   Heska Corporation (NASDAQ: ... and other specialty veterinary products , today announced that ... practices research, tools and metrics for patent analysis and ... Heska,s Science Strength in the top 50 of the ...
...  The United States Patent & Trademark Office (USPTO) has ... ) that the USPTO has rejected all claims by ... 7,357,891 (the ,891 Patent) which is currently being asserted ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ...
Cached Medicine Technology:The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 2The Patent Board Ranks Heska's Science Strength in Biotechnology Industry Top 50 3US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 2US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences' Position 3
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
(Date:7/13/2014)... 2014 According to the Living With ... a comprehensive guide that features a series of tips ... (keratosis pilaris). This guide consists of 14 chapters ... Pilaris? ,     Chapter 2: What Cause KP? , ... Have KP? ,     Chapter 4: Keratosis Pilaris Treatment ...
(Date:7/12/2014)... NY (PRWEB) July 12, 2014 The ... growth over the past five years, buoyed by stable ... sector's supply management system. “Eggs are a relatively affordable ... per capita egg consumption generally grows in line with ... Analyst Will McKitterick. Furthermore, demand for new specialty egg ...
(Date:7/12/2014)... By Dennis Thompson ... -- There,s no way to guarantee that a surgical technique ... tiny incisions won,t increase the risk of spreading cancer to ... Friday. The advisory panel to the Food and Drug ... -- called laparoscopic power morcellation -- should sign a written ...
(Date:7/12/2014)... 12, 2014 The fastest-growing mobile technology ... and measurement of LTE networks continues to grow due ... smart devices have increased mobile data traffic, which is ... (CT&M) market. Communications Test and Measurement equipment comply with ... The Communications Test and Measurement Market is estimated to ...
Breaking Medicine News(10 mins):Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5
... and servants, but Maya commoners found a way to record ... A new study of the objects embedded in the floors ... Belize begins to decode their story. The study, from ... the Journal of Social Archaeology . Maya in ...
... ... website that will help people live a healthy life, offering all-natural, American-made, high-purity supplements. ... (PRWEB) April ... Ophthalmology and the American Board of Environmental Medicine. Along with his many years in ...
... a person contributes to a social network site, the more ... News) -- The secret to online popularity lies in the ... , In a new study, British investigators analyzed the activity ... post entries about their daily lives. The study authors found ...
... ... is responding to a magnitude 6.9 earthquake that has rocked Western China. , ... Lakewood Ranch, FL (Vocus) ... 6.9 earthquake that has rocked Western China., , , , ,The earthquake struck the ...
... free health care worldwide through his nonprofit organization Remote ... as the recipient of the 2010 Inamori Ethics Prize, ... Excellence at Case Western Reserve University. Brock, ... other health care professionals to provide free medical services ...
... on hormone therapy, study found , WEDNESDAY, April 14 ... greater risk for developing blood clots, especially if they,re ... indicate that it is important to consider thromboembolic [blood-clotting] ... those who require endocrine treatment," said Mieke van Hemelrijck, ...
Cached Medicine News:Health News:Classic Maya history is embedded in commoners' homes 2Health News:Classic Maya history is embedded in commoners' homes 3Health News:Enviro-Med -- The New Solution to a Healthier Life 2Health News:Enviro-Med -- The New Solution to a Healthier Life 3Health News:ShelterBox Responds to Earthquake in Western China 2Health News:RAM founder to receive CWRU's Inamori Ethics Prize 2Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 2Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 3
... SET LNOP Blue Sensor is the first ... The LNOP Blue sensor is the first ... for cyanotic infants and children. Cyanotic ... conditions for reliable and accurate pulse oximetry, ...
Inquire...
... The Trinity Biotech Captia™ Varicella- Zoster ... (ELISA) is intended for the detection and ... in human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
ELISA kit for Varicella-zoster IgG....
Medicine Products: